Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 7, 2025 -- For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, according to a study published online Jan. 7 in the Annals of Internal Medicine.
Soichiro Masuda, M.D., Ph.D., from Kyoto City Hospital in Japan, and colleagues examined the risk for cardiovascular events and fracture prevention effects with denosumab versus oral bisphosphonates in dialysis-dependent patients in an observational study using data from a Japanese administrative claims database. The study included 1,032 patients: 658 denosumab users and 374 oral bisphosphonate users.
The researchers found that for MACE, the weighted three-year risk difference was 8.2 percent, with a weighted three-year risk ratio of 1.36 (95 percent confidence interval, 0.99 to 1.87). For composite fractures, the weighted three-year risk difference was −5.3 percent, and the weighted three-year risk ratio was 0.55 (95 percent confidence interval, 0.28 to 0.93).
"Given the high risk for cardiovascular events associated with denosumab in dialysis-dependent patients, comparative effectiveness and safety of these medications should be confirmed in future studies," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Topical Testosterone + Exercise No Aid for Hip Fracture Recovery in Women
TUESDAY, May 20, 2025 -- Topical testosterone therapy does not significantly improve functional outcomes beyond supervised exercise training in older women recovering from a hip...
Air Pollution May Worsen Bone Health in Postmenopausal Women
FRIDAY, May 16, 2025 -- Exposure to air pollution may worsen bone loss in postmenopausal women, according to a study published online April 24 in the Journal of Bone and...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.